AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7049346 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (Cy) alone
Number of subjects: 57
Study 7049346 — intervention group
Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (Cy) + prednisolone (Pred) 100 mg/m2 orally daily for two days
Number of subjects: 57
Study 7049346 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (Cy) alone in small cell carcinoma
Number of subjects: 57
Study 7049346 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (Cy) alone in non-small cell carcinoma
Number of subjects: 57
Study 30823930 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed human amniotic fluid (pAF)
Number of subjects: 6
Study 28937497 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (cognitive remediation)
Number of subjects: 91
Study 28937497 — intervention group
Group type: COMPARATOR
Intervention: General cognitive activation (computer skills training)
Number of subjects: 91
Study 27505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mmol/L ferrous sulfate
Number of subjects: 120
Study 27505987 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mmol/L ferrous fumarate
Number of subjects: 120
Study 27505987 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola (with ferrous sulfate or fumarate)
Number of subjects: 120
Study 27505987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprite (with ferrous sulfate or fumarate)
Number of subjects: 120
Study 27505987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water (with ferrous sulfate or fumarate)
Number of subjects: 120
Study 24999004 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF), 3 mg/kg, 45 min prior to PT
Number of subjects: 12
Study 24999004 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Sodium Bicarbonate (CAF+SB)
Number of subjects: 12
Study 24999004 — intervention group
Group type: COMPARATOR
Intervention: Sodium Bicarbonate (SB), 0.3 g/kg, 75 min prior to PT
Number of subjects: 12
Study 24999004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 12
Study 22973462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense cycling before practice
Number of subjects: 48
Study 22973462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense cycling after practice
Number of subjects: 48
Study 22973462 — intervention group
Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 48
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ) scores for physical limitation
Number of subjects: 873
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ) scores for angina frequency
Number of subjects: 873
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 873
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary disease
Number of subjects: 873
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney disease
Number of subjects: 873
Study 19933930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model with SAQ scores and clinical predictors
Number of subjects: 873
Study 17558830 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg) infusions every two weeks for six weeks, then every four weeks
Number of subjects: 17
Study 17558830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 14726934 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (rEpo) administration starting in the first week of life
Number of subjects: 1090
Study 11226089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sufentanil 5 microg
Number of subjects: 60
Study 11226089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sufentanil 10 microg
Number of subjects: 60
Study 11226089 — intervention group
Group type: COMPARATOR
Intervention: Control (Intraarticular saline and sufentanil 5 microg IV)
Number of subjects: 60
Study 11226089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular sufentanil (5-10 microg)
Number of subjects: 60
Study 9781549 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AT)
Number of subjects: 33
Study 9781549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 33
Study 7870492 — intervention group
Group type: EXPERIMENTAL
Intervention: Wings-out variant of the Mueller-Lyer figure
Number of subjects: 80
Study 7870492 — intervention group
Group type: COMPARATOR
Intervention: Wings-in variant of the Mueller-Lyer figure
Number of subjects: 80
Study 3046383 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient family intervention (IFI) with psychoeducation
Number of subjects: 169
Study 31932093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical medications
Number of subjects: 307
Study 30412479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (UD) for 2 weeks
Number of subjects: 2
Study 28444084 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (35mg capsules, 70mg/day, for 16 weeks)
Number of subjects: 24
Study 28444084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, twice daily)
Number of subjects: 24
Study 25223231 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (GFJ) 250 mL (3 times at 12-hr intervals)
Number of subjects: 12
Study 25223231 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 400 mg (12 hr before tilidine administration)
Number of subjects: 12
Study 25223231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 100 mg solution p.o.
Number of subjects: 12
Study 23238110 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 66
Study 23238110 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 66
Study 23238110 — intervention group
Group type: COMPARATOR
Intervention: Control group (Resistance training)
Number of subjects: 66
Study 21272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy prescribed to patients with diabetes
Number of subjects: 2030
Study 21272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 2030
Study 21272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without diabetes
Number of subjects: 2030
Study 21272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 2030
Study 21272194 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to intensify therapy
Number of subjects: 2030
Study 19428005 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 microg every 6 hours)
Number of subjects: 49
Study 19428005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (200 microg every 6 hours)
Number of subjects: 49
Study 17160912 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (PKC-β isoform-selective inhibitor)
Number of subjects: 0
Study 12805330 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and BCNU (Carmustine)
Number of subjects: 40
Study 12805330 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 40
Study 11037083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) - six 30 min sessions over 3 months
Number of subjects: 68
Study 11037083 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 68
Study 8900907 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 500 mg four times daily plus ranitidine 300 mg four times daily
Number of subjects: 54
Study 8900907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily plus ranitidine 300 mg twice daily
Number of subjects: 54
Study 8900907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg four times daily plus ranitidine 300 mg twice daily
Number of subjects: 54
Study 8900907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg four times daily plus ranitidine 300 mg four times daily
Number of subjects: 54
Study 8900907 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 54
Study 8900907 — intervention group
Group type: COMPARATOR
Intervention: Patients with eradication
Number of subjects: 54
Study 8900907 — intervention group
Group type: COMPARATOR
Intervention: Patients with persistent infection
Number of subjects: 54
Study 8900907 — intervention group
Group type: COMPARATOR
Intervention: Patients with persistent H. pylori
Number of subjects: 54
Study 8900907 — intervention group
Group type: COMPARATOR
Intervention: Patients remaining free of infection
Number of subjects: 54
Study 1992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IgG (0.4 g/kg, repeated on days +1 and +5)
Number of subjects: 62
Study 1992998 — intervention group
Group type: COMPARATOR
Intervention: Human albumin (control group)
Number of subjects: 62
Study 1992998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous IgG
Number of subjects: 62
Study 6391389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (Group A)
Number of subjects: 136
Study 6391389 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (Group B)
Number of subjects: 136
Study 30425012 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (4 treatments on 4 consecutive days)
Number of subjects: 29
Study 30425012 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic pain management recommended by the World Health Organization (control group)
Number of subjects: 29
Study 31210647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 40
Study 29467684 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + PR
Number of subjects: 57
Study 29467684 — intervention group
Group type: COMPARATOR
Intervention: PR-Only
Number of subjects: 57
Study 29467684 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 57
Study 25460016 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (900 billion viable bacteria, comprising 4 strains of Lactobacillus, 3 strains of Bifidobacterium, and 1 strain of Streptococcus salivarius subspecies thermophilus)
Number of subjects: 119
Study 25460016 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (early group, given for 365 days)
Number of subjects: 119
Study 25460016 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (late group, given from days 90 to 365)
Number of subjects: 119
Study 25460016 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (aggregate rates)
Number of subjects: 119
Study 25460016 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 119
Study 25460016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 23896386 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-only mode
Number of subjects: 22
Study 23896386 — intervention group
Group type: COMPARATOR
Intervention: Auditory-visual mode
Number of subjects: 22
Study 21053028 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disc replacement (TDR)
Number of subjects: 152
Study 21053028 — intervention group
Group type: COMPARATOR
Intervention: Lumbar fusion (FUS)
Number of subjects: 152
Study 21053028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness probabilistic analysis
Number of subjects: 152
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 8 microg/kg/d T(4) for 42 days
Number of subjects: 20
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone-treated subjects
Number of subjects: 20
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 4 microg/kg/d T(4) for 42 days
Number of subjects: 20
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 4 microg/kg/d T(4) and 8 microg/kg/d T(4) bolus
Number of subjects: 20
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 4 thyroid hormone treatment arms
Number of subjects: 20
Study 19581264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 8 microg/kg/d arms
Number of subjects: 20
Study 17095411 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of caffeine (Experiment A)
Number of subjects: 24
Study 17095411 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of caffeine (Experiment B)
Number of subjects: 24
Study 17095411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Experiment A)
Number of subjects: 24
Study 17095411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (Experiment B)
Number of subjects: 24
Study 14722642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metamizol
Number of subjects: 30
Study 14722642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol
Number of subjects: 30
Study 14722642 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling
Number of subjects: 30
Study 11463107 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine/doxycycline
Number of subjects: 152
Study 11463107 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 152
Study 11463107 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 152
Study 9516215 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion (EEO)
Number of subjects: 22
Study 9516215 — intervention group
Group type: COMPARATOR
Intervention: End-inspiratory occlusion (EIO)
Number of subjects: 22
Study 9516215 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiratory occlusion (EIO) after lung inflation
Number of subjects: 22
Study 9516215 — intervention group
Group type: EXPERIMENTAL
Intervention: P0.1 during both occlusions
Number of subjects: 22
Study 9516215 — intervention group
Group type: EXPERIMENTAL
Intervention: P10% during EEO
Number of subjects: 22
Study 8090310 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (CL-S)
Number of subjects: 31
Study 8090310 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (CL-T)
Number of subjects: 31
Study 2840630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study 2840630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) during intensive chemotherapy and irradiation
Number of subjects: 0
Study 2840630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) for severe varicella-zoster virus infections
Number of subjects: 0
Study 2840630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) for bacterial infections
Number of subjects: 0
Study 29171129 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTTs) at diagnosis
Number of subjects: 179
Study 29171129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance tests (MMTTs) <6 months after diagnosis
Number of subjects: 179
Study 29171129 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for BMIZ and age
Number of subjects: 179
Study 29171129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose and C‐peptide association
Number of subjects: 179
Study 28302155 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aganirsen
Number of subjects: 333
Study 28302155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 25750280 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-paravertebral anaesthetic with continuing analgesia (PPA)
Number of subjects: 28
Study 25750280 — intervention group
Group type: COMPARATOR
Intervention: Balanced general anaesthesia with opioid analgesia (GA)
Number of subjects: 28
Study 23388470 — intervention group
Group type: EXPERIMENTAL
Intervention: Short storage age blood (1 to 10 days)
Number of subjects: 74
Study 23388470 — intervention group
Group type: COMPARATOR
Intervention: Long storage age blood (21 to 35 days)
Number of subjects: 74
Study 21931984 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular vision/target with image size
Number of subjects: 0
Study 21931984 — intervention group
Group type: COMPARATOR
Intervention: Monocular vision/target with image size
Number of subjects: 0
Study 21931984 — intervention group
Group type: COMPARATOR
Intervention: Binocular vision/point-light target (without image size)
Number of subjects: 0
Study 18274900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus-SDC 2012, 2013 (probiotics)
Number of subjects: 40
Study 18274900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16604476 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive sentinel lymph node patients who did not undergo completion lymphadenectomy
Number of subjects: 134
Study 16604476 — intervention group
Group type: COMPARATOR
Intervention: Positive sentinel lymph node patients who underwent completion lymphadenectomy
Number of subjects: 134
Study 14692209 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography (GC) method for detecting volatile sulfur compounds
Number of subjects: 0
Study 14692209 — intervention group
Group type: COMPARATOR
Intervention: Organoleptic evaluation by trained odor judges
Number of subjects: 0
Study 10869595 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 20
Study 10869595 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study 9197826 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) 30%
Number of subjects: 40
Study 9197826 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) 10%, 20%, or 30%
Number of subjects: 40
Study 9197826 — intervention group
Group type: COMPARATOR
Intervention: Vehicle and light treatment (Control)
Number of subjects: 40
Study 1351703 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure instruction
Number of subjects: 33
Study 1351703 — intervention group
Group type: COMPARATOR
Intervention: Reassurance
Number of subjects: 33
Study 7018846 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral pentaerythritol tetranitrate (PETN)
Number of subjects: 10
Study 7018846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31672469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100mg orally 20min before dressing change)
Number of subjects: 180
Study 31672469 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected music during dressing change
Number of subjects: 180
Study 31672469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100mg orally 20min before dressing change) + Self-selected music
Number of subjects: 180
Study 31672469 — intervention group
Group type: COMPARATOR
Intervention: Routine dressing change only (Control group)
Number of subjects: 180
Study 31245886 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psycho-oncological care (IC)
Number of subjects: 228
Study 28560554 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous postoperative local analgesia with ropivacaine 5 mg/ml
Number of subjects: 100
Study 28560554 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 100
Study 25877710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium ophthalmic solution 0.1%
Number of subjects: 60
Study 25877710 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1% (control)
Number of subjects: 60
Study 23695205 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine (quartile 4)
Number of subjects: 2919
Study 23695205 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine (quartile 3)
Number of subjects: 2919
Study 23695205 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma homocysteine in 677CC and 677CT genotypes
Number of subjects: 2919
Study 23695205 — intervention group
Group type: COMPARATOR
Intervention: MTHFR 677C‐‐>T polymorphism
Number of subjects: 2919
Study 21177528 — intervention group
Group type: EXPERIMENTAL
Intervention: Zen dialogue method with an experienced Zen teacher for 1 day
Number of subjects: 16
Study 21177528 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 16
Study 19699738 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal enemas in addition to conventional therapy
Number of subjects: 101
Study 19699738 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 101
Study 17383295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 655
Study 17383295 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 655
Study 17383295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion
Number of subjects: 655
Study 17383295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 17009844 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Vagimid Dragees) 500 mg metronidazole
Number of subjects: 16
Study 17009844 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation 500 mg metronidazole
Number of subjects: 16
Study 12707123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.08-0.1 mg/kg)
Number of subjects: 82
Study 12707123 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.6-0.8 mg/kg)
Number of subjects: 82
Study 10363683 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVT
Number of subjects: 58
Study 10363683 — intervention group
Group type: COMPARATOR
Intervention: SOHT
Number of subjects: 58
Study 7549385 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuanglian (SHL) aerosol
Number of subjects: 202
Study 2301321 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted diet
Number of subjects: 176
Study 2301321 — intervention group
Group type: COMPARATOR
Intervention: Treatment diet (electrolyte solution then dilute soy formula, dilute cow's milk formula, or undiluted soy formula)
Number of subjects: 176
Study 6951573 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment with comprehensive, assertive and prolonged follow‐up treatment backed by a 24‐hour crisis service.
Number of subjects: 120
Study 6951573 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care and follow‐up (control group).
Number of subjects: 120
Study 31813230 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava (120 mg of kavalactones twice/day)
Number of subjects: 171